Clinical Trials Logo

Dedifferentiated Liposarcoma clinical trials

View clinical trials related to Dedifferentiated Liposarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04242238 Active, not recruiting - Sarcoma Clinical Trials

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Start date: January 22, 2020
Phase: Phase 1
Study type: Interventional

This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.

NCT ID: NCT03651375 Active, not recruiting - Sarcoma Clinical Trials

Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall

UN-RESARC
Start date: February 11, 2017
Phase: Phase 2
Study type: Interventional

After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT) meeting, a patient will receive the first course of chemotherapy - doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm (AI regimen) with prophylactic mesna. Then a patient will be irradiated 5x5 Gy and after radiotherapy he or she will receive two courses of AI within 4-6 weeks, depending on the tolerance. Then the response analysis in DWI-MRI and toxicity assessment and will be performed. On the second MDT meeting, a final decision about resectability of the tumor will be made. In case of resectability, a patient will be referred to surgery.

NCT ID: NCT03307616 Active, not recruiting - Clinical trials for Undifferentiated Pleomorphic Sarcoma

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Start date: October 4, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab with and without ipilimumab and radiation therapy when given before surgery works in treating patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may work better in treating patients with undifferentiated pleomorphic sarcoma.

NCT ID: NCT02846987 Active, not recruiting - Sarcoma Clinical Trials

Study of Abemaciclib in Dedifferentiated Liposarcoma

Start date: July 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of the study drug called Abemaciclib. Abemaciclib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will delay the growth of the cancer or shrink the cancer by at least one quarter compared to its present size. Abemaciclib is not FDA approved and has not been tested in liposarcoma, but it has shrunk tumors in patients with breast cancer, lymphoma, and lung cancer.